Lantern Pharma (NASDAQ:LTRN) is a biopharmaceutical firm focused on advancing cancer treatment through artificial intelligence and machine learning to develop personalized therapies. Leveraging its proprietary RADR® platform, Lantern aims to revolutionize oncology drug discovery and development by identifying biomarker-driven therapies. The company is actively involved in a variety of projects aimed at tackling some of the most pressing challenges in cancer treatment, including difficult-to-treat tumors and resistance to current therapies. Lantern Pharma's objectives are centered around transforming cancer patient outcomes through precision medicine, improving the speed and efficiency of drug development, and ultimately bringing more targeted, effective treatments to market.